Definium Therapeutics (DFTX) Change in Account Payables (2019 - 2026)

Definium Therapeutics (DFTX) has 7 years of Change in Account Payables data on file, last reported at $1.8 million in Q1 2026.

• Change in Account Payables for Q1 2026 came in at $1.8 million, up 589.92% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.9 million (up 243.89% YoY), and the FY2025 annual result was $3.3 million, up 256.96% from the prior year.
• Change in Account Payables advanced to $1.8 million in Q1 2026 per DFTX's latest filing, from -$2.8 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $6.3 million in Q2 2023 and troughed at -$3.5 million in Q4 2023.
• A 5-year average of $174117.6 and a median of $100000.0 in 2022 frame the typical range for Change in Account Payables.
• On a YoY basis, Change in Account Payables climbed as much as 829.78% in 2025 and fell as far as 1889.93% in 2025.
• A 5-year view of Change in Account Payables shows it stood at $1.3 million in 2022, then slumped by 375.73% to -$3.5 million in 2023, then jumped by 96.04% to -$139000.0 in 2024, then slumped by 1889.93% to -$2.8 million in 2025, then surged by 164.35% to $1.8 million in 2026.
• Business Quant data shows DFTX's Change in Account Payables at $1.8 million in Q1 2026, -$2.8 million in Q4 2025, and $3.9 million in Q3 2025.